Key Points
- KindlyMD CEO David Bailey bought 104,833 shares on May 27 at an average price of $4.84 each, a purchase worth about $507,392. After the transaction, he owned 3.12 million shares, increasing his stake by 3.48%.
- The stock recently opened at $5.60 and has been highly volatile, with a market cap of $97.44 million, a 50-day average of $8.21, and a 200-day average of $13.07. Its 1-year range is extremely wide, from $4.50 to $995.60.
- KindlyMD reported weak quarterly results, posting a loss of $15.20 per share on revenue of $2.68 million. Analysts currently have a Hold consensus on the stock, with an average price target of $30.00.
KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) CEO David Bailey purchased 31,500 shares of the firm's stock in a transaction dated Tuesday, May 26th. The shares were bought at an average cost of $5.58 per share, with a total value of $175,770.00. Following the purchase, the chief executive officer directly owned 3,015,528 shares of the company's stock, valued at approximately $16,826,646.24. This represents a 1.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
KindlyMD Stock Performance
KindlyMD stock opened at $5.60 on Friday. The company has a 50 day moving average price of $8.21 and a 200-day moving average price of $13.07. KindlyMD, Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $995.60. The company has a market capitalization of $97.44 million, a PE ratio of -0.13 and a beta of 17.12.
KindlyMD (NASDAQ:NAKA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share for the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. The company had revenue of $2.68 million for the quarter. On average, analysts forecast that KindlyMD, Inc. will post -16.8 earnings per share for the current year.
Key Headlines Impacting KindlyMD
Here are the key news stories impacting KindlyMD this week:
- Positive Sentiment: CEO David Bailey bought 104,833 shares at an average price of $4.84, adding to a series of recent open-market purchases and lifting his ownership stake, which may reassure investors about management’s confidence in KindlyMD. Article Title
- Positive Sentiment: Maxim Group reiterated a Buy rating and $30 price target, with forecasted improvement in later-period earnings, which could help support sentiment around NAKA. Article Title
- Neutral Sentiment: Maxim’s earnings estimates still call for losses in the near term, but they model a shift to profitability in some periods of fiscal 2027, suggesting the turnaround story remains speculative. Article Title
- Negative Sentiment: The company’s latest reported quarter showed a large EPS loss and weak profitability metrics, which continue to highlight execution risk for investors. Article Title
Institutional Investors Weigh In On KindlyMD
Several hedge funds have recently modified their holdings of NAKA. Sagespring Wealth Partners LLC purchased a new stake in KindlyMD during the fourth quarter valued at approximately $28,000. SG Americas Securities LLC purchased a new position in KindlyMD in the fourth quarter worth $61,000. Virtu Financial LLC purchased a new position in KindlyMD in the fourth quarter worth $151,000. J. Derek Lewis & Associates Inc. purchased a new position in KindlyMD in the fourth quarter worth $167,000. Finally, Truist Financial Corp purchased a new position in KindlyMD in the fourth quarter worth $176,000.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on NAKA shares. B. Riley Financial lowered their price target on shares of KindlyMD from $40.00 to $20.00 and set a "buy" rating for the company in a research report on Monday, February 23rd. TD Cowen started coverage on shares of KindlyMD in a research report on Friday, April 10th. They issued a "buy" rating and a $40.00 price target for the company. Wall Street Zen raised shares of KindlyMD to a "sell" rating in a research report on Saturday, May 23rd. Maxim Group lowered their price target on shares of KindlyMD from $60.00 to $30.00 and set a "buy" rating for the company in a research report on Monday, April 6th. Finally, Weiss Ratings raised shares of KindlyMD from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, May 11th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $30.00.
View Our Latest Stock Analysis on NAKA
About KindlyMD
(
Get Free Report)
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
